The contribution of multicellular model organisms to neuronal ceroid lipofuscinosis research.

Batten disease Disease mechanism Experimental therapy Lysosomal storage disorder Model organism Neuronal ceroid lipofuscinosis Pathology

Journal

Biochimica et biophysica acta. Molecular basis of disease
ISSN: 1879-260X
Titre abrégé: Biochim Biophys Acta Mol Basis Dis
Pays: Netherlands
ID NLM: 101731730

Informations de publication

Date de publication:
01 09 2020
Historique:
received: 26 06 2019
revised: 14 11 2019
accepted: 15 11 2019
pubmed: 30 11 2019
medline: 22 12 2020
entrez: 30 11 2019
Statut: ppublish

Résumé

The NCLs (neuronal ceroid lipofuscinosis) are forms of neurodegenerative disease that affect people of all ages and ethnicities but are most prevalent in children. Commonly known as Batten disease, this debilitating neurological disorder is comprised of 13 different subtypes that are categorized based on the particular gene that is mutated (CLN1-8, CLN10-14). The pathological mechanisms underlying the NCLs are not well understood due to our poor understanding of the functions of NCL proteins. Only one specific treatment (enzyme replacement therapy) is approved, which is for the treating the brain in CLN2 disease. Hence there remains a desperate need for further research into disease-modifying treatments. In this review, we present and evaluate the genes, proteins and studies performed in the social amoeba, nematode, fruit fly, zebrafish, mouse and large animals pertinent to NCL. In particular, we highlight the use of multicellular model organisms to study NCL protein function, pathology and pathomechanisms. Their use in testing novel therapeutic approaches is also presented. With this information, we highlight how future research in these systems may be able to provide new insight into NCL protein functions in human cells and aid in the development of new therapies.

Identifiants

pubmed: 31783156
pii: S0925-4439(19)30340-0
doi: 10.1016/j.bbadis.2019.165614
pii:
doi:

Substances chimiques

Membrane Proteins 0
Tpp1 protein, mouse 0
Tripeptidyl-Peptidase 1 0
TPP1 protein, human EC 3.4.14.9

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

165614

Subventions

Organisme : Medical Research Council
ID : MR/P012965/1
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/N008472/1
Pays : United Kingdom
Organisme : CIHR
ID : PJT165873
Pays : Canada

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Auteurs

Robert J Huber (RJ)

Department of Biology, Trent University, Peterborough, Ontario K9L 0G2, Canada.

Stephanie M Hughes (SM)

Department of Biochemistry, School of Biomedical Sciences, Brain Health Research Centre and Genetics Otago, University of Otago, Dunedin, New Zealand.

Wenfei Liu (W)

School of Pharmacy, University College London, London, WC1N 1AX, UK.

Alan Morgan (A)

Department of Cellular and Molecular Physiology, Institute of Translational Medicine, University of Liverpool, Crown St., Liverpool L69 3BX, UK.

Richard I Tuxworth (RI)

Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham B15 2TT, UK.

Claire Russell (C)

Dept. Comparative Biomedical Sciences, Royal Veterinary College, Royal College Street, London NW1 0TU, UK. Electronic address: crussell@rvc.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH